ASX
Paradigm Biopharmaceuticals
PAR:ASX•Healthcare
Sensitive ASX Announcement
Primary Endpoint Achieved in Phase 2 MPS VI Trial
Published: 09/02/24, 09:04am (AEST)•6 pages